Conjunctival hyperemia bimatoprost

Topical PGE2 and PGF2qi significantly reduce intraocular pressure for at least 24 hours and are used in the treatment of glaucoma. Derivatives of the isopropyl ester of PGF2qi appear to be the most effective. Transient ocular adverse effects include conjunctival hyperemia, local irritation, intermittent photophobia, and pain in the eye (66-68). Newer derivatives, such as latanoprost, travoprost, and bimatoprost, appear to be better tolerated, with less severe and less frequent adverse effects (69). They reduce intraocular pressure by increasing uveoscleral outflow. 

Bimatoprost can cause gradual darkening of the color of the eyes and the eyelid skin, increased thickness, numbers and darkness of eyelashes, conjunctival hyperemia, and ocular pruritus (1). Darkening of the iris occurs in 1.1% of patients (2). 

Prostaglandin analogues Latanoprost Bimatoprost Unoprostone Travoprost Inaease aqueous outflow Blurry vision, conjunctival hyperemia, iris pigmentation, increase in eyelash length and coarseness... 

In a meta-analysis of all clinical trials with a direct comparison of prostaglandins (latanoprost, bimatoprost, and travoprost) in which adverse events were reported, there was a higher incidence of conjunctival hyperemia in patients who used bimatoprost 0.03%. [34 ]. 

A lower rate of conjunctival hyperemia has been reported with latanoprost in comparison with bimatoprost and travoprost, and there has been a meta-analysis of 13 randomized clinical trials in 2222 patients with ocular hypertension and/or glaucoma, comparing latanoprost with bimatoprost and travoprost, either together or in separated studies [36 ]. Five of the studies compared latanoprost and travoprost, seven compared latanoprost and bimatoprost, and one compared latanoprost, travoprost, and bimatoprost. The combined results showed that latanoprost was associated with a lower incidence of conjunctival hyperemia than both travoprost... 

Sensory systems Eyes Conjunctival hyperemia has been studied in patients using bimatoprost 0.03% as initial therapy and compared with that in patients in whom latanoprost was replaced by bimatoprost changes in hyperemia scores from baseline were highly significant only in first-line therapy [37 ]. 

---